SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Aptus Pharma Ltd

BSE: 544529 NSE: ISIN: INE15XJ01010
  |   Sector:  Miscellaneous   |   Industry:  Trading

Snapshot

Q.1 Which industry/sub-sector does Aptus Pharma Ltd belong to?
Aptus Pharma Ltd belongs to the Miscellaneous sector, operating specifically within the Trading segment.
Q.2 Is Aptus Pharma Ltd a good quality company?
Aptus Pharma Ltd is a weak quality company, based on a inconsistent 3-year financial track record.
Q.3 Is Aptus Pharma Ltd undervalued or overvalued?
Aptus Pharma Ltd appears Overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Aptus Pharma Ltd a good buy now?
Aptus Pharma Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Return on capital employed (ROCE) of Aptus Pharma Ltd?
Aptus Pharma Ltd Return on capital employed is 38.22% for FY-2025, which is above its 3-year historical median of 26.47%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 14%, indicating value creation.
Q.2 Return on Asset of Aptus Pharma Ltd?
Aptus Pharma Ltd Return on Asset is 19.48%, which is above its 3-year historical median of 9.88%, indicating improved asset utilization efficiency.
Q.3 Return on Equity (ROE) of Aptus Pharma Ltd?
Aptus Pharma Ltd Return on equity is 70.99% for FY-2025, which is above its 3-year historical median of 58.36%, indicating the business is making better use of its shareholders capital.
Q.4 Gross Profit margin of Aptus Pharma Ltd?
Aptus Pharma Ltd Gross profit margin which is the profit after deduction of direct costs, is 17.9% for FY-2025, which is above its 3-year median of 7.4%, indicating increasing margins.
Q.5 Operating Profit Margin of Aptus Pharma Ltd?
Aptus Pharma Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 20.09% for FY-2025, which is above its 3-year median of 9.41% indicating increasing margins.
Q.6 Net Profit Margin of Aptus Pharma Ltd?
Aptus Pharma Ltd Net Profit Margin is 12.62% for FY-2025, is above with its 3-year median of 4.47%, indicating increasing margins.
Current Level 3-year
Historic Median
Gross Profit Margin 17.9 7.4
Operating Profit Margin 20.09 9.41
Net Profit Margin 12.62 4.47
Q.7 Debt to Equity ratio of Aptus Pharma Ltd?
Aptus Pharma Ltd Debt-to-Equity ratio is 1.49, which is above with the industry average of 0.19, indicating higher debt levels in the industry.
Q.8 Debt to cash flow from operations of Aptus Pharma Ltd?
Aptus Pharma Ltd Debt to cash flow from operations is -5.63, which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Aptus Pharma Ltd?
Promoters hold 72.89% of the Aptus Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Aptus Pharma Ltd vs industry peers?
Aptus Pharma Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 13.25%, indicating slower growth and losing its market share.
Profit Metrics
Current Level 3-year
Industry Median
Revenue Growth - 13.3
Gross Profit Growth 300 NAN
Operating Profit Growth 150 16.4
Net Profit Growth 200 NAN
Operating Efficiency
Current Level 3-year
Industry Median
Asset Turnover 1.57 0.97
ROE 70.99 3.61
ROCE 38.22 4.53
Cash Conversion Cycle (days) 119.81 66

Valuation & price assessment

Q.1 Stock return of Aptus Pharma Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price
CAGR		 - - - -
Q.3 Valuation ratios of Aptus Pharma Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios compare with 3-year historical median and industry numbers?
Valuation Ratios Current 3-year
Historic Median		 3-year
Industry Median
Price to Earnings 62.73 49.12 35.02
Price to Book 14.5 7.62 1.68
Price to Sales 6.22 6.02 2.16
EV to EBITDA 38.91 31.94 15.53

Check more companies

1. Aditya Infotech
2. Aegis Logistics
3. Redington
4. RRP Semiconductor
5. Honasa Consumer
6. Lloyds Enterprises
7. MMTC
8. Cello World
9. Jeena Sikho Life
10. SG Mart

Check trending companies

1. JSW Infrastructure Ltd.
2. Aditya Birla Fashion and Retail Ltd.
3. Zydus Lifesciences Ltd.
4. Techno Electric & Engineering Company Ltd.
5. Cello World Ltd.
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×